Feb 05th 2013 - Edison Investment Research today published a report on Bionomics entitled "Eclipse Boosts Oncology Pipeline". In summary, the report says:
Bionomics’ acquisition of San Diego-based Eclipse Therapeutics last year brought in new technology and expertise in antibody and cancer stem cells, complementing its existing capabilities in the development of small molecule therapeutics. The company’s lead compound remains BNC105, which is in Phase II trials for renal cell carcinoma and ovarian cancer and has recently become the lead vascular disrupting agent in commercial development. Eclipse added BNC101, a late preclinical antibody against LGR5, a cancer stem cell target. Meanwhile, anti-anxiety compound IW‐2143, licensed to Ironwood Pharmaceuticals, is now in a Phase I trial in the US.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »